Gut Microbiota and Parkinson's Disease: Potential Links and the Role of Fecal Microbiota Transplantation

Overview

Journal Front Aging Neurosci

Specialty Geriatrics

Date 2024 Dec 16

PMID 39679259

Authors

Maosen Feng

Zhiyan Zou

Pingping Shou

Wei Peng

Mingxue Liu

Xiaoan Li

Affiliations

Soon will be listed here.

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disease worldwide and seriously affects the quality of life of elderly patients. PD is characterized by the loss of dopaminergic neurons in the substantia nigra as well as abnormal accumulation of α-synuclein in neurons. Recent research has deepened our understanding of the gut microbiota, revealing that it participates in the pathological process of PD through the gut-brain axis, suggesting that the gut may be the source of PD. Therefore, studying the relationship between gut microbiota and PD is crucial for improving our understanding of the disease's prevention, diagnosis, and treatment. In this review, we first describe the bidirectional regulation of the gut-brain axis by the gut microbiota and the mechanisms underlying the involvement of gut microbiota and their metabolites in PD. We then summarize the different species of gut microbiota found in patients with PD and their correlations with clinical symptoms. Finally, we review the most comprehensive animal and human studies on treating PD through fecal microbiota transplantation (FMT), discussing the challenges and considerations associated with this treatment approach.

References

van Kessel S, Frye A, El-Gendy A, Castejon M, Keshavarzian A, van Dijk G . Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson's disease. Nat Commun. 2019; 10(1):310. PMC: 6338741. DOI: 10.1038/s41467-019-08294-y. View

Hansen C, Angot E, Bergstrom A, Steiner J, Pieri L, Paul G . α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest. 2011; 121(2):715-25. PMC: 3026723. DOI: 10.1172/JCI43366. View

Qian Y, Yang X, Xu S, Wu C, Song Y, Qin N . Alteration of the fecal microbiota in Chinese patients with Parkinson's disease. Brain Behav Immun. 2018; 70:194-202. DOI: 10.1016/j.bbi.2018.02.016. View

Shannon K, Keshavarzian A, Mutlu E, Dodiya H, Daian D, Jaglin J . Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord. 2011; 27(6):709-15. DOI: 10.1002/mds.23838. View

LeWitt P . Levodopa for the treatment of Parkinson's disease. N Engl J Med. 2008; 359(23):2468-76. DOI: 10.1056/NEJMct0800326. View

Hansson O . Biomarkers for neurodegenerative diseases. Nat Med. 2021; 27(6):954-963. DOI: 10.1038/s41591-021-01382-x. View

Sheng H, Xue Y, Zhao W, Hovde C, Minnich S . O157:H7 Curli Fimbriae Promotes Biofilm Formation, Epithelial Cell Invasion, and Persistence in Cattle. Microorganisms. 2020; 8(4). PMC: 7232329. DOI: 10.3390/microorganisms8040580. View

Mulak A . An overview of the neuroendocrine system in Parkinson's disease: what is the impact on diagnosis and treatment?. Expert Rev Neurother. 2019; 20(2):127-135. DOI: 10.1080/14737175.2020.1701437. View

Gundacker N, Tamhane A, Walker J, Morrow C, Rodriguez J . Comparative effectiveness of faecal microbiota transplant by route of administration. J Hosp Infect. 2017; 96(4):349-352. DOI: 10.1016/j.jhin.2017.05.004. View

10.

Haifer C, Paramsothy S, Kaakoush N, Saikal A, Ghaly S, Yang T . Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2021; 7(2):141-151. DOI: 10.1016/S2468-1253(21)00400-3. View

11.

Liu J, Wang F, Liu S, Du J, Hu X, Xiong J . Sodium butyrate exerts protective effect against Parkinson's disease in mice via stimulation of glucagon like peptide-1. J Neurol Sci. 2017; 381:176-181. DOI: 10.1016/j.jns.2017.08.3235. View

12.

Dominguez-Bello M, Godoy-Vitorino F, Knight R, Blaser M . Role of the microbiome in human development. Gut. 2019; 68(6):1108-1114. PMC: 6580755. DOI: 10.1136/gutjnl-2018-317503. View

13.

Nishiwaki H, Ito M, Hamaguchi T, Maeda T, Kashihara K, Tsuboi Y . Short chain fatty acids-producing and mucin-degrading intestinal bacteria predict the progression of early Parkinson's disease. NPJ Parkinsons Dis. 2022; 8(1):65. PMC: 9160257. DOI: 10.1038/s41531-022-00328-5. View

14.

Zhou X, Lu J, Wei K, Wei J, Tian P, Yue M . Neuroprotective Effect of Ceftriaxone on MPTP-Induced Parkinson's Disease Mouse Model by Regulating Inflammation and Intestinal Microbiota. Oxid Med Cell Longev. 2021; 2021:9424582. PMC: 8687851. DOI: 10.1155/2021/9424582. View

15.

Boktor J, Sharon G, Verhagen Metman L, Hall D, Engen P, Zreloff Z . Integrated Multi-Cohort Analysis of the Parkinson's Disease Gut Metagenome. Mov Disord. 2023; 38(3):399-409. DOI: 10.1002/mds.29300. View

16.

Walter J, Shanahan F . Fecal microbiota-based treatment for recurrent Clostridioides difficile infection. Cell. 2023; 186(6):1087. DOI: 10.1016/j.cell.2023.02.034. View

17.

Sun M, Zhu Y, Zhou Z, Jia X, Xu Y, Yang Q . Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson's disease mice: Gut microbiota, glial reaction and TLR4/TNF-α signaling pathway. Brain Behav Immun. 2018; 70:48-60. DOI: 10.1016/j.bbi.2018.02.005. View

18.

Xie Z, Zhang M, Luo Y, Jin D, Guo X, Yang W . Healthy Human Fecal Microbiota Transplantation into Mice Attenuates MPTP-Induced Neurotoxicity via AMPK/SOD2 Pathway. Aging Dis. 2023; 14(6):2193-2214. PMC: 10676800. DOI: 10.14336/AD.2023.0309. View

19.

Holvoet T, Joossens M, Vazquez-Castellanos J, Christiaens E, Heyerick L, Boelens J . Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial. Gastroenterology. 2020; 160(1):145-157.e8. DOI: 10.1053/j.gastro.2020.07.013. View

20.

Hou Y, Shan C, Zhuang S, Zhuang Q, Ghosh A, Zhu K . Gut microbiota-derived propionate mediates the neuroprotective effect of osteocalcin in a mouse model of Parkinson's disease. Microbiome. 2021; 9(1):34. PMC: 7849090. DOI: 10.1186/s40168-020-00988-6. View